INCB186748 + gemcitabine + nab-paclitaxel

INCB186748 + gemcitabine + nab-paclitaxel is an investigational **combination therapy** for advanced or metastatic solid tumors, with particular focus on **pancreatic cancer** harboring KRAS G12D mutations. INCB186748 is a **KRAS G12D inhibitor** under development by Incyte, administered orally, targeting tumors bearing this specific mutation[3]. Gemcitabine is a nucleoside analog antineoplastic agent that inhibits DNA synthesis, and nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, which stabilizes microtubules and inhibits cell division[2][6]. The combination of gemcitabine and nab-paclitaxel is well-established in pancreatic cancer therapy, offering synergistic tumor reduction and improved intratumoral drug concentrations[2][4][6].

Other names

gemcitabinealbumin-bound paclitaxel